Stockscreener 앱 받기
1.80
0.56%
0.01
시간 외 거래:
1.78
-0.02
-1.11%
전일 마감가:
$1.79
열려 있는:
$1.81
하루 거래량:
1.32M
Relative Volume:
0.74
시가총액:
$390.54M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-3.4615
EPS:
-0.52
순현금흐름:
$-23.38M
1주 성능:
-9.55%
1개월 성능:
+34.33%
6개월 성능:
+56.52%
1년 성능:
+80.00%
1일 변동 폭
$1.77
$1.84
1주일 범위
$1.76
$2.00
52주 변동 폭
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AKBA | 1.80 | 390.54M | 194.75M | -51.26M | -23.38M | -0.52 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Yahoo Finance UK
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance
Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider
Akebia Therapeutics Prepares for Vafseo Launch - TipRanks
Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - citybiz
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan
A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News
Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada
Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.15%
자본화:
|
볼륨(24시간):